跳至主要内容
临床试验/NCT00973180
NCT00973180已完成不适用

Enhanced Prescription Drug Label to Improve Patient Understanding and Use

Northwestern University2 个研究点 分布在 1 个国家目标入组 850 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
850
试验地点
2
主要终点
Understanding of prescription medication

研究概览

简要总结

The overall objective of this study is to test the efficacy of an evidence-based, enhanced Rx container label design to improve patients' understanding of instructions for use.

The investigators will conduct a randomized controlled trial (N=960) to evaluate the efficacy of the enhanced Rx container label to improve patients' understanding of actual prescribed medicines, compared to a standard label format. Patients with type II diabetes and/or hypertension at safety-net clinics affiliated with one central-fill pharmacy (Nova Scripts Central - NSC) receive their prescribed medicines from this location. Recruited subjects in this study will be randomly assigned to either intervention (enhanced Rx container label) or control (standard Rx label). All pill-form, regular dosing schedule medicines, including diabetes and hypertensive (i.e. ACE inhibitor) medicines associated with patients' treatment will be labeled according to study arm by the central-fill pharmacy. Study subjects will be interviewed at the time of dispensing the prescribed medicines at the clinic, again three months later (dispensing of refill), and finally nine months after baseline (dispensing of refill). Pharmacy refill data and medical record information - linked at these clinics - will be collected for exploratory analyses. Patients' ability to read and demonstrate Rx label instructions, including auxiliary warnings, will be the primary outcomes. Other exploratory outcome measures will also be measured, including 1) adverse effects associated with medication use defined by a) the rate of physician visits, b) the rate of emergency room visits, and c) the rate of hospitalizations and hospital admissions via emergency rooms for medication side effects (e.g. hyperglycemia or hypoglycemia); and 2) health outcome as measured by the change from baseline in hemoglobin A1c (HbA1c) and blood pressure measurements. Data from the actual use trial will be processed, reviewed, analyzed (in order of hypotheses), and reports prepared during the final months of this last phase of the study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
30 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Type II diabetes or hypertension in their medical chart.
  • 30 years or older.
  • Fluent in English.

排除标准

  • Uncorrectable hearing or visual impairment.
  • Too ill to participate.

结局指标

主要结局

Understanding of prescription medication

时间窗: Baseline, 3 months, 9 months

次要结局

  • Change in HbA1c or blood pressure readings(Baseline, 3 months, 9 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael S. Wolf

Professor

Northwestern University

研究点 (2)

Loading locations...

相似试验

Enhanced Prescription Drug Label to Improve Patient... | 临床试验